Rosiglitazone maleate/metformin hydrochloride: A new formulation therapy for type 2 diabetes

Drugs of Today

Volumn 40, Issue 7, 2004, Pages 633-643

  Cox, Sandra L ^a  

^a Medical Information Department   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; AMILORIDE; BIGUANIDE DERIVATIVE; CHLORAMPHENICOL; DIGOXIN; FUROSEMIDE; GLIPIZIDE; IBUPROFEN; MEGLITINIDE; METFORMIN; MORPHINE; NIFEDIPINE; ORAL ANTIDIABETIC AGENT; ORAL CONTRACEPTIVE AGENT; PROBENECID; PROPRANOLOL; RANITIDINE; REPAGLINIDE; RIFAMPICIN; ROSIGLITAZONE; SALICYLIC ACID DERIVATIVE; SULFONAMIDE; SULFONYLUREA DERIVATIVE; VANCOMYCIN;

ANEMIA; ARTHRALGIA; BACKACHE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HEADACHE; HUMAN; HYPERGLYCEMIA; INJURY; INSULIN RESISTANCE; INSULIN SENSITIVITY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; REVIEW; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; RANDOMIZED CONTROLLED TRIALS; THIAZOLIDINEDIONES;

EID: 4644264940     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2004.40.7.850480     Document Type: Review

References (52)

1. International Diabetes Federation. Diabetes mellitus. Facts & Figures, 2003.
2. World Health Organization. Diabetes mellitus. Fact sheet, number 138, revised April 2002.
3. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1999, 22 (Suppl. 1): S5-S20.
4. Haffner, S.M., Lehto, S., Rönnemaa, T., Pyörälä, K., Laakso, M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339: 229-34.
5. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352: 854-65.
6. Goldberg, R.B., Mellies, M.J., Sacks, F.M. et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup Analyses in the Cholesterol and Recurrent Events (CARE) trial. Circulation 1998, 98: 2513-9.
7. Hansson, L., Zanchetti, A., George Carruthers, S. et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998, 351: 1755-62.
8. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2003, 26 (Suppl. 1): S33-S50.
9. Chan, J.L., Abrahamson, M.J. Pharmacological management of type 2 diabetes mellitus: Rationale for rational use of insulin. Mayo Clin Proc 2003, 78: 459-67.
10. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP), expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J Am Med Assoc 2001; 285: 2486-97.
11. Alberti, G. A desktop guide to type 2 diabetes mellitus. European Diabetes Policy Group 1998-1999 International Diabetes Federation European Region. Exp Clin Endocrinol Diabetes 1999, 107: 390-420.
12. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346: 393-403.
13. Tuomilehto, J., Lindström, J., Eriksson, J.G. et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344: 1343-50.
14. DeFronzo, R.A. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999, 131: 281-303.
15. Turner, R.C., Cull, C.A., Frighi, V., Holman, R.R. and UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). J Am Med Assoc 1999, 281: 2005-12.
16. Bailey, C.J., Path, M.R.C., Turner, R.C. Metformin. N Engl J Med 1996, 334: 574-9.
17. Cusi, K., Consoli, A., DeFronzo, R.A. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996, 81: 4059-67.
18. Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., Gerich, J.E. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995, 333: 550-4.
19. Inzucchi, S.E., Maggs, D.G., Spollett, G.R. et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998, 338: 867-72.
20. Zhou, G., Myers, R., Li, Y. et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001, 108: 1167-74.
21. Musi, N., Hirshman, M.F., Nygren, J. et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002, 51: 2074-81.
22. DeFronzo, R.A., Goodman, A.M. and The Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 541-9.
23. Robinson, A.C., Burke, J., Robinson, S., Johnston, D.G., Elkeles, R.S. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control. Diabetes Care 1998, 21: 701-5.
24. United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS) 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. Br Med J 1995, 310: 83-8.
25. Johansen, K. Efficacy of metformin in the treatment of NIDDM. Diabetes Care 1999, 22: 33-7.
26. Goldstein, B.J., Pans, M., Rubin, C.J. Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/ metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea. Clin Ther 2003, 25: 890-903.
27. GlaxoSmithKline. Avandia prescribing information. Research Triangle Park, North Carolina, USA, Mar 2003.
28. O'Moore-Sullivan, T.M., Prins, J.B. Thiazolidinediones and type 2 diabetes: New drugs for an old disease. Med J Austr 2002, 176: 381-6.
29. Olefsky, J.M. Treatment of insulin resistance with peroxisome proliferator-activated receptor α agonists. J Clin Invest 2000, 106: 467-72.
30. Mayerson, A.B., Hundal, R.S., Dufour, S. et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002, 51: 797-802.
31. Schoonjans, K., Auwerx, J. Thiazolidinediones: An update. Lancet 2000, 355: 1008-10.
32. Lehman, J.M., Moore, L.B., Smith-Oliver, T.A., Wilkison, W.O., Willson, T.M., Kliewer, S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 1995, 270: 12953-6.
33. Day, C. Thiazolidinediones: A new class of antidiabetic drugs. Diabet Med 1999, 16: 179-92.
34. Patel, J., Anderson, R.H., Rappaport, E.B. Rosiglitazone monotherapy improves glycemic control in patients with type 2 diabetes: A twelve-week, randomized, placebo-controlled study. Diabetes Obes Met 1999, 1: 165-72.
35. Lebovitz, H.E., Dole, J.F., Patwardhan, R., Rappaport, E.B., Freed, M.I. and Rosiglitazone Clinical Trials Study Group. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001, 86: 280-8.
36. Phillips, L.S., Grunberger, G., Miller, E. et al. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001, 24: 308-15.
37. Goldstein, B.J., Cobitz, A.R., Hand, L.M., Chen H. Are the metabolic effects of rosiglitazone influenced by baseline glycemic control? Curr Med Res Opin 2003, 19: 192-9.
38. Nolan, J.J., Jones, N.P., Patwardhan, R., Deacon, L. F. Rosiglitazone taken once daily provides effective glycemic control in patients with type 2 diabetes mellitus. Diabet Med 2000, 17: 287-294.
39. St. John Sutton, M., Rendell, M., Dandona, P. et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002, 25: 2058-64.
40. Haffner, S.M., Greenberg, A.S., Weston, W.M., Chen, H., Williams, K., Freed, M.I. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002, 106: 679-84.
41. Bakris, G., Viberti, G., Weston, W.M., Heise, M., Porter L.E., Freed, M.I. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 2003, 17: 7-12.
42. Wolffenbuttel, B.H., Gomis, R., Squatrito, S., Jones, N.P., Patwardhan, R.N. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycemic control in type 2 diabetes. Diabet Med 2000, 17: 40-7.
43. Yang, J., Di, F., He, R. et al. Effect of addition of low-dose rosiglitazone to sulphonylurea therapy on glycemic control in type 2 diabetic patients. Chin Med J 2003, 116: 785-7.
44. Raskin, P., Rendell, M., Riddle, M.C. et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001, 24: 1226-32.
45. Fonseca, V., Rosenstock, J., Patwardhan, R., Salzman, A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus. A randomized controlled trial. J Am Med Assoc 2000, 283: 1695-1702.
46. Gómez-Pérez, F.J., Fanghänel-Salmón, G., Antonio Barbosa, J. et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Met Res Rev 2002, 18: 127-34.
47. Jones, T.A., Sautter, M., van Gaal, L.F., Jones, N.P. Addition of rosiglitazone is most effective in obese, insulin-resistant patients with type 2 diabetes. Diabetes Obes Metab 2003, 5: 163-70.
48. Gould, E., Cobitz, A. Long-term durability of rosiglitazone as monotherapy or in combination therapy in patients with type 2 diabetes. 84th Annual Meeting Endocrinol Soc (Jun 19-22, San Francisco) 2002, Abst. P1-60.
49. GlaxoSmithKline. Avandamet prescribing information. Research Triangle Park, North Carolina, USA, Aug 2003.
50. DiCicco, R.A., Allen, A., Carr, A., Fowles, S., Jorkasky, D.K., Freed, M.I. Rosiglitazone does not alter the pharmacokinetics of metformin. J Clin Pharmacol 2000, 40: 1280-5.
51. Park, J.Y., Kim, K.A., Kang, M.H., Shin, J.G. Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. Clin Pharmacol Ther 2004, 75: 157-62.
52. Baillargeon, J.P., Jakubowicz, D.J., Iuorno, M.J., Jakubowiz, S., Nestler, J.E. Effects of metformin and rosiglitazone, alone and in combination, in lean women with polycystic ovary syndrome and normal indices of insulin sensitivity. 84th Annual Meeting Endocrinol Soc (Jun 19-22, San Francisco) 2002, Abst. OR10-1.